Qiagen : Q3 due 3 November – Set to benefit from surge of coronavirus cases
>Q3 to be better than guided - We estimate Q3 to be up by 4.3% y-o-y (+3% y-o-y excl. forex) on sales, reaching $ 504.8m. This is above the consensus (Vara; $ 497m) and also above the guidance (flat revenues y-o-y excl. forex). New FY and Q3 guidance was given early July. Since then, there has been a surge in infections with the coronavirus cases in the northern hemisphere in particular. This should have resulted in higher testing levels and therefore higher coronavir...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.